Selected article for: "antiviral activity and clinical efficacy"
Author: Figueroa, Juan Manuel; Lombardo, Mónica Edith; Dogliotti, Ariel; Flynn, Luis Pedro; Giugliano, Robert; Simonelli, Guido; Valentini, Ricardo; Ramos, Agñel; Romano, Pablo; Marcote, Marcelo; Michelini, Alicia; Salvado, Alejandro; Sykora, Emilio; Kniz, Cecilia; Kobelinsky, Marcelo; Salzberg, David Manuel; Jerusalinsky, Diana; Uchitel, Osvaldo
Title: Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease
  • Cord-id: juofmvz2
  • Document date: 2021_10_1
    • ID: juofmvz2
    Snippet: BACKGROUND: Iota-Carrageenan (I-C) is a sulfate polysaccharide synthesized by red algae, with demonstrated antiviral activity and clinical efficacy as nasal spray in the treatment of common cold. In vitro, I-C inhibits SARS-CoV-2 infection in cell culture. RESEARCH QUESTION: Can a nasal spray with Iota-Carrageenan be useful in the prophylaxis of COVID-19 in health care workers managing patients with COVID-19 disease? STUDY DESIGN AND METHODS: This is a pilot pragmatic multicenter, randomized, do
    Document: BACKGROUND: Iota-Carrageenan (I-C) is a sulfate polysaccharide synthesized by red algae, with demonstrated antiviral activity and clinical efficacy as nasal spray in the treatment of common cold. In vitro, I-C inhibits SARS-CoV-2 infection in cell culture. RESEARCH QUESTION: Can a nasal spray with Iota-Carrageenan be useful in the prophylaxis of COVID-19 in health care workers managing patients with COVID-19 disease? STUDY DESIGN AND METHODS: This is a pilot pragmatic multicenter, randomized, double-blind, placebo-controlled study assessing the use of a nasal spray containing I-C in the prophylaxis of COVID-19 in hospital personnel dedicated to care of COVID-19 patients. Clinically healthy physicians, nurses, kinesiologists and other health care providers managing patients hospitalized for COVID-19 were assigned in a 1:1 ratio to receive four daily doses of I-C spray or placebo for 21 days. The primary end point was clinical COVID-19, as confirmed by reverse transcriptase polymerase chain reaction testing, over a period of 21 days. The trial is registered at ClinicalTrials.gov (NCT04521322). RESULTS: A total of 394 individuals were randomly assigned to receive I-C or placebo. Both treatment groups had similar baseline characteristics. The incidence of COVID-19 differs significantly between subjects receiving the nasal spray with I-C (2 of 196 [1.0%]) and those receiving placebo (10 of 198 [5.0%]). Relative risk reduction: 79.8% (95% CI 5.3 to 95.4; p=0.03). Absolute risk reduction: 4% (95% CI 0.6 to 7.4). INTERPRETATION: In this pilot study a nasal spray with I-C showed significant efficacy in preventing COVID-19 in health care workers managing patients with COVID-19 disease. CLINICAL TRIALS REGISTRATION: NCT04521322.

    Search related documents:
    Co phrase search for related documents
    • absolute risk reduction and acute respiratory syndrome coronavirus: 1
    • acceptable test and acute respiratory syndrome: 1, 2
    • acceptable test and acute respiratory syndrome coronavirus: 1
    • active concentration and acute respiratory syndrome: 1, 2, 3, 4
    • active concentration and acute respiratory syndrome coronavirus: 1, 2, 3, 4
    • active principle and acute respiratory syndrome: 1, 2
    • active treatment and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active treatment and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active treatment and loss reduction: 1
    • active treatment group and acute respiratory syndrome: 1
    • active treatment group and acute respiratory syndrome coronavirus: 1
    • active vitro and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • active vitro and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome and administrative cost: 1
    • acute respiratory syndrome and long term medium: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory syndrome and long term medium short: 1
    • acute respiratory syndrome and loss reduction: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory syndrome and low remain: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory syndrome coronavirus and low remain: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12